top of page

 Intellia Therapeutics, Inc. (NTLA) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA). Investors who purchased Intellia securities are encouraged to obtain additional information and assist the investigation.


The investigation concerns whether Intellia has violated federal securities laws.

On August 4, 2022, Intellia issued a press release “report[ing] operational highlights and financial results for the second quarter ended June 30, 2022.”  Among other items, Intellia reported a net loss of $100.7 million, or $1.33 per diluted share, slightly worse than the consensus estimate for net loss of $1.31 per diluted share.  Intellia also disclosed plans to focus exclusively on developing ex vivo (out of the body) allogeneic (commonly referred to as off-the-shelf) cell therapies.  In connection with this shift in focus, Intellia advised that the Company was discontinuing a clinical study evaluating the experimental cell therapy NTLA-5001.  On this news, Intellia’s stock price fell $6.27 per share, or 8.74%, to close at $65.43 per share on August 4, 2022.


If you are aware of any facts relating to this investigation or purchased Intellia shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.

bottom of page